Abstract
As a hypoglycemic agent, 5-methylpyrazole-3-carboxylic acid was found to be 116 times more potent orally than tolbutamide in glucose-injected, fasted, intact rats. U-19425 increases glucose oxidation in vivo and in epididymal adipose tissue. It also inhibits the release of free fatty acid (FFA) from adipose tissue in vitro. The pyrazole lowers blood sugar and plasma FFA of eviscerated rats and is effective in decreasing fasting blood sugar levels of alloxan diabetic rats which do not respond to tolbutamide. U-19425 markedly depresses plasma FFA of fasting man.
The data presented suggest that the primary action of U-19425 is on fat metabolism. The data are consistent with the hypothesis that the effect of U-19425 on glucose oxidation and blood sugar depression may be secondary to the initial plasma FFA depression.
Footnotes
- Accepted June 29, 1965.
- The Williams & Wilkins Comapny
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|